It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
This study shows an association between human adenovirus (HAdV) infections occurring after mesenchymal stromal cell (MSC) infusion and decreased survival in patients treated for severe steroid-refractory acute graft-versus-host disease. In vitro data demonstrate a suppressive effect of MSCs on proliferation and activation of HAdV-specific T cells, but results do not support a negative impact on antiviral T-cell-driven immune responses in vivo; however, the benefits with MSCs seem to outweigh the potentially increased risk of infections.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department of Pediatrics, Immunology Section, Hematology/Oncology and Hematopoietic Stem Cell Transplantation, Leiden University Medical Center, Leiden, The Netherlands
2 Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
3 Department of Pediatrics, Immunology Section, Hematology/Oncology and Hematopoietic Stem Cell Transplantation, Leiden University Medical Center, Leiden, The Netherlands; Department of Hematology/Oncology and Hematopoietic Stem Cell Transplantation, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada